Within the framework of the LXXII Annual Meeting of the Spanish Society of Neurology, Nutricia will present the Lipididiet clinical trial where it has been shown for the first time that, in the initial stages of Alzheimer’s without dementia, Souvenaid can be beneficial in the long term, as well as in various aspects cognitive capacity, especially memory and functional capacity.
the clinical trial LipiDiDietalready developed for three years, deals with the Alzheimer’s disease in the early stage of the disease, also known as mild cognitive impairment (MCI). This clinical trial has evaluated the effects of Souvenaid nutritional intervention about him cognitive state and other symptoms related to this pathology.
As indicated by Nutricia, the results that will be exhibited at the which is held from November 23 to December 3, show that this nutritional intervention slowed down the cognitive and memory declinemaintained functional capacity and observed a in the patients. In addition, the results also reveal that the benefits of this intervention increased with its long-term use.
Souvenaid is a food for special medical purposes for the dietary management of patients with mild Alzheimer’s disease.
He LipiDiDiet clinical trialpublished in the magazine Alzheimer’s & Dementia, has been prepared by a research consortium formed by world leaders in Neurology and has included more than 300 patients. He Dr. Rafael Blesadirector of the Neurology Service of the Hospital de la Santa Creu i Sant Pau (Barcelona) and in charge of presenting the results at the SEN Meeting, highlights that “It is great news that the LipiDiDiet study was able to show that Souvenaid is effective in managing Alzheimer’s in the stage in which, despite afflicting memory failures, patients continue to lead a normal life (Mild Cognitive Impairment or Prodromal Alzheimer’s)».
«These results have a double value, since for the first time it has been shown that, in the initial stages of Alzheimer’s, without dementia, Souvenaid may be beneficial in the long term; and, furthermore, the benefit in this double-blind study encompasses various aspects of cognitive ability, especially memory and functional abilityas well as a reduction in brain atrophy compared to the placebo group”, adds Dr. Blesa.
is the longest double-blind, randomized, controlled clinical trial ever conducted in patients with mild cognitive impairment (DCL). The nutritional intervention was performed with Souvenaid containing Fortasyn Connecta combination of phospholipids, choline, uridine and omega-3 polyunsaturated fatty acids, designed to meet the needs of nutritional needs specific to people in the early stages of Alzheimer’s disease.
He early diagnostic Alzheimer’s is key to improving cognitive function
Alzheimer’s disease is a progressive neurodegenerative disorderwho currently suffer from 800,000 people in Spain, according to the SEN. Neuropathological features generally begin 15 to 20 years before clear cognitive symptoms. In this early stage of the disease, patients usually show obvious short-term memory deficits. Furthermore, it is estimated that 80% of Alzheimer’s cases that are still mild are undiagnosed.
In this sense, the early diagnostic of Alzheimer’s disease in the stage of mild cognitive impairment is key to improving cognitive function and its progression. Pharmacological intervention in these stages is not generally recommended, with the exception of treatment of depression or other neuropsychiatric symptoms.
“Establishing an early diagnosis of Alzheimer’s disease in its early stages, what we call the prodromal stage, represents a window of opportunity for interventions that improve brain health or cognitive functioning and be able to handle modifiable risk factors involved in disease progression”, explains Dr. Blesa.
“If until now for the prodromal MCI-Alzheimer stage we could recommend those measures aimed at preventing the disease, such as monitoring of vascular risk factors, the consumption of the Mediterranean diet and physical exercise, now we can incorporate into our therapeutic arsenal and apply itas in the standards cited above, on a daily, continuous and long-term basis”, concludes Dr. Blesa.
Dr. Rafael Blesa’s presentation will take place next November 23 at 7:00 p.m. at the LXXII Annual Meeting of the Spanish Society of Neurology (SEN).